Novo Nordisk STEP Young meets primary endpoint; two heart studies halted
Novo Nordisk said STEP Young Phase 3 met its primary endpoint: 40.4% of children aged 6 to under 12 were off obesity after 68 weeks on semaglutide plus lifestyle versus 0% on placebo. Two heart-disease studies were stopped.